<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>CF on ER Andrinopoulou</title>
    <link>https://www.erandrinopoulou.com/tags/cf/</link>
    <description>Recent content in CF on ER Andrinopoulou</description>
    <generator>Source Themes Academic (https://sourcethemes.com/academic/)</generator>
    <language>en-us</language>
    <lastBuildDate>Tue, 02 Jul 2019 00:00:00 +0000</lastBuildDate>
    
	    <atom:link href="https://www.erandrinopoulou.com/tags/cf/index.xml" rel="self" type="application/rss+xml" />
    
    
    <item>
      <title>Investigate the natural progression and assessing the treatment effectiveness on lung function decline with the US Cystic Fibrosis Foundation Patient Registry</title>
      <link>https://www.erandrinopoulou.com/project/cff/</link>
      <pubDate>Tue, 02 Jul 2019 00:00:00 +0000</pubDate>
      
      <guid>https://www.erandrinopoulou.com/project/cff/</guid>
      <description>&lt;p&gt;Active collaboration with Dr. Rhonda Szczesniak, Department of Pediatrics, University of Cincinnati, Division of Biostatistics &amp;amp; Epidemiology, Cincinnati Children&amp;rsquo;s Hospital Medical Center, Cincinnati, United States and the Cystic Fibrosis Foundation.&lt;/p&gt;
&lt;p&gt;To evaluate analytic approaches to assess changes in FEV1 decline. We focus on&lt;/p&gt;
&lt;p&gt;1 Natural progression of lung function.&lt;/p&gt;
&lt;p&gt;2a Lung function progression before and after treatment (ivacaftor) initiation.&lt;/p&gt;
&lt;p&gt;2b Between treated and untreated groups of subjects.&lt;/p&gt;
&lt;p&gt;3 Variability in lung function decline before and after treatment (ivacaftor) initiation.&lt;/p&gt;
</description>
    </item>
    
  </channel>
</rss>
